Caprion Biosciences Inc., a Montreal-based contract research organization, said its blood-based protein biomarker findings suggest host protein expression changes can be detected in early stage Mycobacterium tuberculosis (Mtb) infection.
Using ProteoCarta, Caprion’s mass spectrometry (MS) and multiple reactions monitoring (MRM-MS) platform, researchers were able to detect the protein expression even before tuberculin skin testing conversion and development of latent M. tuberculosis infection (LTBI).
“These findings are very significant and could impact the way we approach treatment, providing a solid basis to accelerate the development of predictive testing,” said Eustache Paramithiotis, vice-president of discovery at Caprion.
Paramithiosis led the study in collaboration Dr. Charles Bark, and Dr. W. Henry Boom, from Case Western Reserve University.
The new data, recently published in EbioMedicine, expands and strengthens Caprion’s existing portfolio of biomarkers assays for predicting and monitoring of active TB, supporting clients who are developing TB therapeutics and diagnostics.
LTBI is a state of persistent immune response resulting from Mtb infection but without evidence of clinically active TB.
Current immune-based tests for Mtb infection (LTBI) cannot distinguish recent from remote Mtb infection. Approximately 10 per cent of people with LTBI will develop active TB and are the primary source of TB spreading. Their identification is critical to efforts aimed at controlling TB.
In this proteomic study, host proteins expressed differentially between patients uninfected and individuals exposed to M. tuberculosis through contact with family members, which were followed over a period of 12 months.
Caprion’s bioinformatic analysis determined multiple biomarker signatures correlating with subsequent development of an immune response recognizing Mtb. These biomarker signatures may demonstrate individuals recently infected by Mtb at high risk for developing active tuberculosis.